Answers are grounded in this paper and cite their sources.
Background The University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) is used commonly in clinical trials to evaluate dyspnea in patients with idiopathic pulmonary fibrosis (IPF). Previously, the minimal clinically important difference (MCID) for UCSD-SOBQ was estimated at 8 points for patients with IPF with severe impairment as determined by lung function tests. Research Question What is the MCID threshold for UCSD-SOBQ worsening in patients with IPF and less physiologic impairment? Study Design and Methods Pooled data from patients with baseline forced vital capacity (FVC) of ≥ 50% predicted enrolled in the 2 randomized phase 3 CAPACITY trials of pirfenidone (ClinicalTrials.gov Identifiers: NCT00287716 and NCT00287729) were analyzed. Over the 72-week treatment period, the MCIDs for the UCSD-SOBQ were estimated using anchor-based methods by comparing changes in UCSD-SOBQ scores with values for stability/improvement vs worsening in 4 candidate anchors: FVC, diffusing capacity of the lungs for carbon monoxide (Dlco), 6-minute walk distance (6MWD), and St George's Respiratory Questionnaire activity domain (SGRQ-A). Anchors that correlated with UCSD-SOBQ scores for at least 1 measurement (correlation coefficient ≥ 0.3) were included for MCID determination in a receiver operating characteristics approach. Results Overall, UCSD-SOBQ score changes were similar within stability/improvement and worsening categories for FVC, Dlco, and 6MWD anchors. For the SGRQ-A anchor, for stability/improvement, UCSD-SOBQ changes were lower than for the other anchors; for worsening, changes were greater. Based on suitable correlation coefficients, FVC, 6MWD, and SGRQ-A were the anchors used to triangulate the MCID. Optimal anchor cut points (MCID) for worsening were 6 for FVC, 4.3 for 6MWD, and 5.8 for SGRQ-A, which resulted in a z-transformed weighted average for UCSD-SOBQ worsening of 5.97. Interpretation Our results show that in patients with IPF and mild or moderate physiologic impairment, the UCSD-SOBQ has a MCID for worsening of 4 to 6 with a point estimate of 6. Trial Registry ClinicalTrials.gov; No.: NCT00287716 and NCT00287729; URL: www.clinicaltrials.gov
No takes yet. Share an insight, caveat, or question.
Aronson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: